Trevi Therapeutics' Haduvio Sees $15B Market Potential
· news
Trevi Therapeutics’ Haduvio: A Glimmer of Hope for Chronic Cough Sufferers?
Trevi Therapeutics’ recent stock price surge has raised eyebrows among investors and analysts. At a European conference, the company’s CEO, Jennifer Good, and Chief Development Officer, James Cassella, touted their oral treatment candidate, Haduvio, as a promising solution for patients with refractory chronic cough or idiopathic pulmonary fibrosis.
According to Trevi Therapeutics’ presentation, clinical trials showed that Haduvio significantly reduced cough episodes. The addressable market is substantial: the total market size for chronic cough is projected to grow from $9 billion in 2024 to an estimated $14-15 billion by 2035, with a compound annual growth rate of 6 percent across major regions.
This growth potential has attracted institutional investors, with over 40 hedge funds holding positions in Trevi Therapeutics as of the first quarter. However, their collective holdings decreased by 2 percent during this period, indicating some weakening conviction.
The market opportunity for Haduvio is vast, but what does it mean for patients? For decades, those suffering from chronic cough have relied on off-label neuromodulators with high adverse event rates. An estimated 100 million patients globally lack access to FDA-approved treatment options. If Haduvio secures regulatory approval, it could be a game-changer.
Trevi Therapeutics plans to initiate an adaptive design Phase 2b clinical trial in the second half of 2026, with top-line results expected in 2027. This will be a critical test for Haduvio’s efficacy and potential long-term impact on patient care. The broader implications of Haduvio’s success or failure extend far beyond Trevi Therapeutics itself.
Haduvio’s extended-release formulation of nalbuphine may offer a safer, more effective alternative to existing treatments, but it also raises questions about long-term dependence on opioids. Will this therapy perpetuate the cycle, or will it mark a turning point in our treatment of chronic cough? As investors and analysts continue to scrutinize Trevi Therapeutics’ prospects, one thing is clear: the stakes are high for patients, pharmaceutical companies, and regulators alike.
The success or failure of Haduvio will serve as a litmus test for our ability to tackle some of medicine’s most intractable challenges. Ultimately, the future of Haduvio hangs precariously in the balance – along with that of hundreds of millions of patients worldwide who remain desperate for relief from chronic cough.
Reader Views
- RJReporter J. Avery · staff reporter
The Trevi Therapeutics hype is well-deserved, but investors would do well to scrutinize the company's clinical trial design. An adaptive Phase 2b study can be a double-edged sword: while allowing for more efficient data collection and decision-making, it also increases the risk of inconclusive results. If Haduvio falls short, Trevi Therapeutics' stock price could plummet, but more likely is that the company will pivot to another asset in their pipeline, leaving investors wondering what went wrong.
- CMColumnist M. Reid · opinion columnist
The $15 billion market potential for Trevi Therapeutics' Haduvio is tantalizing, but investors should be wary of overhyping this oral treatment candidate. The clinical trial results are promising, but regulatory approval is far from a guarantee. What's more concerning is the lack of transparency around the efficacy of Haduvio in addressing idiopathic pulmonary fibrosis, which makes up nearly half of its projected market. If Trevi Therapeutics can't provide clear evidence of its treatment's benefits for this complex and often deadly condition, investors and patients may be left disappointed by their expectations.
- CSCorrespondent S. Tan · field correspondent
The hype surrounding Trevi Therapeutics' Haduvio is understandable, given its potential to disrupt a lucrative market. However, it's crucial not to overlook the challenges ahead. Regulatory approval will be just the first hurdle; getting doctors to prescribe a new treatment that competes with established off-label options won't be easy either. Moreover, the projected market growth may not entirely translate into profits for Trevi Therapeutics if competition from generic or biosimilar versions emerges soon after launch.